PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI)

Historical Holders from Q1 2014 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
PBYI on Nasdaq
Shares outstanding
49,633,071
Price per share
$5.95
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
34,367,867
Total reported value
$182,467,133
% of total 13F portfolios
0%
Share change
+1,569,433
Value change
+$11,618,135
Number of holders
131
Price from insider filings
$5.95
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ACORN BIOVENTURES, L.P. 8% +19% $11,859,557 +$1,988,442 3,940,052 +20% Anders Hove 31 Dec 2024
BlackRock, Inc. 5.6% $8,366,151 2,779,452 BlackRock, Inc. 31 Mar 2025
MILLENNIUM MANAGEMENT LLC 3.9% $5,701,319 1,894,126 Millennium Management LLC 31 Dec 2024
As of 30 Sep 2025, PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) has 131 institutional shareholders filing 13F forms. They hold 34,367,867 shares. of 49,633,071 outstanding shares (69%) .

Top 25 institutional shareholders own 59% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
ACORN CAPITAL ADVISORS, LLC 8.3% 4,131,299 0% 11% $21,937,198
VANGUARD GROUP INC 7.4% 3,691,720 -0.4% 0% $19,603,033
BlackRock, Inc. 7.2% 3,577,877 -6.7% 0% $18,998,527
RENAISSANCE TECHNOLOGIES LLC 4.3% 2,151,213 +15% 0.02% $11,422,941
ACADIAN ASSET MANAGEMENT LLC 4.1% 2,053,305 +2.2% 0.02% $10,900,000
AMERICAN CENTURY COMPANIES INC 3% 1,483,188 +10% 0% $7,875,728
DIMENSIONAL FUND ADVISORS LP 2.6% 1,271,878 +11% 0% $6,751,930
GEODE CAPITAL MANAGEMENT, LLC 2% 983,522 +1.2% 0% $5,223,376
Russell Investments Group, Ltd. 1.9% 964,693 +4823365% 0.01% $5,122,519
Connor, Clark & Lunn Investment Management Ltd. 1.9% 943,472 +4.8% 0.02% $5,009,836
KENNEDY CAPITAL MANAGEMENT LLC 1.7% 867,630 -12% 0.1% $4,607,115
O'SHAUGHNESSY ASSET MANAGEMENT, LLC 1.7% 828,221 +89% 0.03% $4,397,854
STATE STREET CORP 1.5% 748,658 +1.9% 0% $3,975,374
LSV ASSET MANAGEMENT 1.1% 559,921 +4.5% 0.01% $2,973,000
MARSHALL WACE, LLP 1.1% 557,548 +659% 0% $2,960,578
NORTHERN TRUST CORP 1.1% 526,736 +74% 0% $2,796,968
D. E. Shaw & Co., Inc. 1% 498,598 -22% 0% $2,647,555
RITHOLTZ WEALTH MANAGEMENT 0.95% 470,767 +139% 0.05% $2,499,773
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 0.94% 464,734 +2.9% 0% $2,467,738
GLOBEFLEX CAPITAL L P 0.91% 452,606 0% 0.37% $2,403,338
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.87% 433,561 +114% 0.05% $2,302,209
MORGAN STANLEY 0.76% 378,082 +17% 0% $2,007,615
UBS Group AG 0.76% 376,091 +37% 0% $1,997,043
Bank of New York Mellon Corp 0.72% 355,368 +3.3% 0% $1,887,005
SEI INVESTMENTS CO 0.7% 347,234 0% 0% $1,843,818

Institutional Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 11,859 $69,649 -$327,711 $5.95 5
2025 Q3 34,367,867 $182,467,133 +$11,618,135 $5.31 131
2025 Q2 32,782,327 $112,437,236 +$8,596,760 $3.43 121
2025 Q1 30,413,709 $90,020,693 +$2,952,602 $2.96 116
2024 Q4 29,394,127 $89,648,308 -$7,801,084 $3.05 111
2024 Q3 29,741,414 $75,860,432 -$5,784,759 $2.55 100
2024 Q2 30,964,332 $100,942,686 -$1,236,662 $3.26 98
2024 Q1 29,743,016 $157,668,204 +$17,052,475 $5.30 93
2023 Q4 26,608,129 $115,214,198 +$4,767,738 $4.33 82
2023 Q3 25,704,166 $67,598,924 -$2,428,856 $2.63 67
2023 Q2 26,576,438 $93,807,644 -$4,382,380 $3.53 67
2023 Q1 27,855,345 $86,065,002 -$527,663 $3.09 77
2022 Q4 27,496,427 $116,318,396 -$138,759 $4.23 86
2022 Q3 27,643,484 $65,508,451 -$1,989,453 $2.37 71
2022 Q2 27,896,143 $79,494,556 -$4,139,901 $2.85 77
2022 Q1 29,904,506 $86,071,643 -$477,483 $2.88 95
2021 Q4 30,286,741 $92,179,926 -$39,504,988 $3.04 96
2021 Q3 32,161,600 $225,498,183 -$28,665,006 $7.01 112
2021 Q2 34,758,681 $319,233,355 -$17,282,962 $9.18 118
2021 Q1 36,622,682 $355,897,814 +$13,747,740 $9.72 117
2020 Q4 35,303,327 $362,460,750 -$9,270,334 $10.26 120
2020 Q3 38,674,035 $390,198,466 +$12,930,607 $10.09 128
2020 Q2 35,087,132 $365,869,787 -$6,707,284 $10.43 124
2020 Q1 36,622,300 $308,895,684 +$43,630,089 $8.44 121
2019 Q4 31,346,607 $274,240,276 -$64,624,795 $8.75 129
2019 Q3 36,566,451 $393,738,047 +$16,141,553 $10.77 138
2019 Q2 34,765,202 $441,844,355 -$103,904,681 $12.71 132
2019 Q1 34,161,633 $1,323,863,060 +$17,647,411 $38.79 156
2018 Q4 35,195,489 $716,303,054 -$227,829,815 $20.35 137
2018 Q3 35,649,697 $1,634,461,087 -$26,392,843 $45.85 154
2018 Q2 35,935,120 $2,125,191,869 -$1,056,901 $59.15 169
2018 Q1 35,574,353 $2,419,811,616 -$81,238,705 $68.05 168
2017 Q4 36,157,207 $3,573,656,170 -$112,228,539 $98.85 194
2017 Q3 36,681,359 $4,391,736,256 +$169,794,588 $119.75 170
2017 Q2 35,525,549 $3,104,620,640 +$57,539,772 $87.40 152
2017 Q1 37,964,211 $1,412,435,790 +$191,118,200 $37.20 135
2016 Q4 34,931,958 $1,072,410,439 +$72,943,477 $30.70 128
2016 Q3 29,992,904 $2,010,275,475 +$5,538,941 $67.05 145
2016 Q2 31,810,369 $947,699,404 +$39,640,223 $29.79 107
2016 Q1 30,412,423 $892,904,817 -$134,999,214 $29.37 114
2015 Q4 32,269,617 $2,529,775,949 +$177,573,758 $78.40 131
2015 Q3 30,151,475 $2,271,836,092 -$40,738,025 $75.36 159
2015 Q2 30,442,694 $3,553,611,040 -$40,063,235 $116.75 193
2015 Q1 29,120,599 $6,873,292,525 +$477,852,182 $236.11 194
2014 Q4 27,148,671 $5,140,326,488 +$68,524,432 $189.27 183
2014 Q3 26,680,747 $6,365,417,896 +$471,513,554 $238.57 182
2014 Q2 25,372,332 $1,674,353,490 -$43,122,202 $66.00 132
2014 Q1 25,068,536 $2,610,636,453 +$107,147,987 $104.14 130